R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Patients initially are randomized into 4 arms:
Arm I: R-DA-EPOCH; Arm II: R-DA-EPOCH + auto-SCT; Arm III: R-CEOP90; Arm IV: R-CEOP90 +
auto-SCT.
Patients who achieved complete remission (CR) or partial remission (PR) after 6 cycles of
R-DA-EPOCH or R-CEOP 90, continue to have 2 more cycles for consolidation in each arm (Arm I
and Arm III), or undergo stem cell harvest and auto-HSCT following standard institutional
protocols. (Arm II and Arm IV).
The overall purpose of the study is to determine if R-CEOP90 followed by auto-HSCT has
similar efficacy compared to that with R-DA-EPOCH.